search
Back to results

PROBESITY-2: Synbiotics in Pediatric Obesity (PROBESITY-2)

Primary Purpose

Obesity, Childhood, Obesity, Adolescent

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Synbiotic
Sponsored by
Eskisehir Osmangazi University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Obesity, Childhood focused on measuring Obesity, Synbiotic, Microbiota, Microbiome

Eligibility Criteria

8 Years - 17 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Children and adolescents
  • Aged between 8 to 17 years old with exogenous obesity

Exclusion Criteria:

  • Children and adolescents with endogenous obesity
  • Children with adolescents with a history of gastrointestinal surgery
  • Children with adolescents with chronic intestinal disorders including inflammatory bowel disease
  • Children receiving probiotics and /or antibiotics 8 weeks prior this study.

Sites / Locations

  • Eskisehir Osmangazi University Faculty of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Synbiotic

Placebo

Arm Description

Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 x10 9CFU/sachet), fructooligosaccharydes (FOS) 625 mg, oral sachet daily, for 12 weeks

Oral sachet daily for 12 weeks

Outcomes

Primary Outcome Measures

Change as percentage for weight and body mass index.
% reduction comparing to baseline

Secondary Outcome Measures

Change as percentage of anthropometric measurement
Waist circumference, hip circumference, waist/hip ratio, waist/height ratio
Change of glucose metabolism
Reduction as percentage of HOMA-IR
Change of lipid metabolism
Serum total cholesterol, LDL-C, HDL-C, serum triglyceride
Change of Intestinal microbiota composition
Change of predominant bacterial genera

Full Information

First Posted
December 6, 2021
Last Updated
December 20, 2021
Sponsor
Eskisehir Osmangazi University
search

1. Study Identification

Unique Protocol Identification Number
NCT05162209
Brief Title
PROBESITY-2: Synbiotics in Pediatric Obesity
Acronym
PROBESITY-2
Official Title
Effects Of Synbiotic Supplementation On Anthropometric Measurements, Glucose Metabolism, Lipid Parameters And Intestinal Microbiota Composition In Children With Exogenous Obesity: (Probesity-2 Study)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
June 1, 2019 (Actual)
Primary Completion Date
April 30, 2021 (Actual)
Study Completion Date
September 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Eskisehir Osmangazi University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The global obesity epidemic presents an unprecedented challenge to the public health worldwide. The factors associated with obesity are complex, and include health behaviours, such as eating habits and daily physical activity, and broader social, environmental and biological determinants that influence these health behaviours. The intestinal microbiota has several beneficial functions related to host health and accumulating evidence indicates that the gut microbiota plays a significant role in the development of obesity, obesity-associated inflammation and insulin resistance. Differences in community composition, functional genes and metabolic activities of the gut microbiota appear to distinguish lean vs obese individuals, suggesting that gut 'dysbiosis' contributes to the development of obesity and/or its complications. Recent studies have suggested some beneficial effects of probiotics and/or prebiotics on obesity and metabolic syndrome in adults; such experience is limited in children and adolescents. There are limited information about the synbiotics in children and adolescent with obesity.The mechanism of action of probotics on obesity are scarce and microbiota restoration/reshaping might be the one. The objective of this study tested the effects of a multispecies synbiotic on anthropometric measurement, glucose metabolism, lipid parameters and intestinal microbiota in children with exogenous obesity.
Detailed Description
The global obesity epidemic presents an unprecedented challenge to the public health worldwide. The factors associated with obesity are complex, and include health behaviours, such as eating habits and daily physical activity, and broader social, environmental and biological determinants that influence these health behaviours. The intestinal microbiota has several beneficial functions related to host health and accumulating evidence indicates that the gut microbiota plays a significant role in the development of obesity, obesity-associated inflammation and insulin resistance. Differences in community composition, functional genes and metabolic activities of the gut microbiota appear to distinguish lean vs obese individuals, suggesting that gut 'dysbiosis' contributes to the development of obesity and/or its complications. Recent studies have suggested some beneficial effects of probiotics and/or prebiotics on obesity and metabolic syndrome in adults; such experience is limited in children and adolescents. There are limited information about the synbiotics in children and adolescent with obesity.The mechanism of action of probotics on obesity are scarce and microbiota restoration/reshaping might be the one. The objective of this study tested the effects of a multispecies synbiotic on anthropometric measurement, glucose metabolism, lipid parameters and intestinal microbiota in children with exogenous obesity. This is a randomized, double-blind, placebo-controlled clinical study with 61 children, aged between 8 to 17 years-old, with exogenous obesity which received a daily dose of a multispecies symbiotic formulation or a placebo for 12 weeks. At entry, the anthropometric measures included weight, height, waist and hip circumference were recorded. Waist circumference to height ratio, waist circumference to hip circumference ratio and body mass index (BMI) was calculated. Venous blood samples were drawn after a minimum 8 hours fasting for measures including serum glucose, insulin, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, C-reactive protein (CRP), erythrocyte sedimentation rate; at admission and 12 weeks later. Both groups were treated with a standard diet and increased physical activity. Patients were randomly allocated into two groups in a ratio of 1:1. Randomization with permutated blocks was done using the online software tool. First group received a daily synbiotic supplementation which consisted of a daily probiotic mixture including Lactobacillus acidophilus), Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 x109CFU/sachet), fructooligosaccharydes (FOS) 625 mg, lactulose 400 mg, vitamin A (6 mg), B1 (1.8 mg), B2 (1.6 mg), B6 (2.4 mg), E (30 mg), C (75 mg) for 12 weeks. Second group received placebo for 12 weeks. Each visit (Day 0 and 12 weeks later), stool samples were also collected. The V3 and V4 regions of the 16S rRNA gene were amplified following the 16S Metagenomic Sequencing Library Preparation. The primary end point of this study was to evaluate the effect of the multispecies synbiotic would on weight loss (reduction as percentage for weight and body mass index). Secondary endpoints were the evolution of the other anthropometeic measurements, glucose and lipid metabolism and intestinal microbiota composition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Childhood, Obesity, Adolescent
Keywords
Obesity, Synbiotic, Microbiota, Microbiome

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, double blind, placebo controlled clinical study
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Synbiotic
Arm Type
Experimental
Arm Description
Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 x10 9CFU/sachet), fructooligosaccharydes (FOS) 625 mg, oral sachet daily, for 12 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Oral sachet daily for 12 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Synbiotic
Intervention Description
Oral sachet, for 12 weeks
Primary Outcome Measure Information:
Title
Change as percentage for weight and body mass index.
Description
% reduction comparing to baseline
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change as percentage of anthropometric measurement
Description
Waist circumference, hip circumference, waist/hip ratio, waist/height ratio
Time Frame
12 weeks
Title
Change of glucose metabolism
Description
Reduction as percentage of HOMA-IR
Time Frame
12 weeks
Title
Change of lipid metabolism
Description
Serum total cholesterol, LDL-C, HDL-C, serum triglyceride
Time Frame
12 weeks
Title
Change of Intestinal microbiota composition
Description
Change of predominant bacterial genera
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Children and adolescents Aged between 8 to 17 years old with exogenous obesity Exclusion Criteria: Children and adolescents with endogenous obesity Children with adolescents with a history of gastrointestinal surgery Children with adolescents with chronic intestinal disorders including inflammatory bowel disease Children receiving probiotics and /or antibiotics 8 weeks prior this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ener C Dinleyici, MD
Organizational Affiliation
Eskisehir Osmangazi University Faculty of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Eskisehir Osmangazi University Faculty of Medicine
City
Eskisehir
State/Province
Odunpazarı
ZIP/Postal Code
26040
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35845797
Citation
Kilic Yildirim G, Dinleyici M, Vandenplas Y, Dinleyici EC. Effects of Multispecies Synbiotic Supplementation on Anthropometric Measurements, Glucose and Lipid Parameters in Children With Exogenous Obesity: A Randomized, Double Blind, Placebo-Controlled Clinical Trial (Probesity-2 Trial). Front Nutr. 2022 Jul 1;9:898037. doi: 10.3389/fnut.2022.898037. eCollection 2022.
Results Reference
derived

Learn more about this trial

PROBESITY-2: Synbiotics in Pediatric Obesity

We'll reach out to this number within 24 hrs